2020 Year in Review - Ovarian Cancer
In the year 2020, we have witnessed an unprecedented evolution in medicine, as we adjusted our clinical practices, research programs, and educational vehicles to meet the challenges of the COVID-19 pandemic.
Personalized starting doses of niraparib based on body weight and platelet count are associated with reductions in thrombocytopenia and other hematologic events.
A recent study explores niraparib’s efficacy, safety, and effect on quality of life in compared age-groups.
Robotic interval debulking surgery is efficient and safe when treating patients with advanced ovarian cancer who are receiving neoadjuvant chemotherapy.
In the phase 2 OVARIO study, median progression-free survival (PFS) has not yet been reached in women with advanced ovarian cancer who are being treated with the combination of niraparib and bevacizumab after response to first-line platinum-based chemotherapy plus bevacizumab. The combination did not appear to cause cumulative toxicities.
Researchers evaluated the connections between safety and efficacy and rucaparib pharmacokinetic exposure in patients with recurrent ovarian cancer.
Treatment with niraparib improves progression-free survival (PFS) in patients with ovarian cancer regardless of their biomarker status.
In patients with newly diagnosed, advanced ovarian cancer and BRCA mutation, olaparib demonstrated a consistently high reduction in the risk for cancer progression and death.
Although researchers noted a trend toward increased incidence of secondary hematologic malignancy in patients with newly diagnosed ovarian cancer treated with poly (ADP-ribose) polymerase (PARP) inhibitors, the difference was not statistically significant.
NOVA clinical trial data outcomes were superior to the real-world outcomes for niraparib, highlighting the critical need for better understanding of variables impacting poly (ADP-ribose) polymerase (PARP) inhibitor outcomes in clinical practice.
